Cargando…
Prolyl 4‐hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls
Melanoma is an unpredictable, highly metastatic malignancy, and treatment of advanced melanoma remains challenging. Novel molecular markers based on the alterations in gene expression and the molecular pathways activated or deactivated during melanoma progression are needed for predicting the course...
Autores principales: | Eriksson, Johanna, Le Joncour, Vadim, Jahkola, Tiina, Juteau, Susanna, Laakkonen, Pirjo, Saksela, Olli, Hölttä, Erkki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138405/ https://www.ncbi.nlm.nih.gov/pubmed/32053263 http://dx.doi.org/10.1002/1878-0261.12649 |
Ejemplares similares
-
Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression
por: Eriksson, Johanna, et al.
Publicado: (2016) -
Reduced Bone Mass in Collagen Prolyl 4‐Hydroxylase P4ha1
(+/−); P4ha2
(−/−) Compound Mutant Mice
por: Tolonen, Jussi‐Pekka, et al.
Publicado: (2022) -
Pelvic sentinel lymph nodes have minimal impact on survival in melanoma patients
por: Vuoristo, Mikko, et al.
Publicado: (2021) -
Divergent roles of lysyl oxidase family members in ornithine decarboxylase- and RAS-transformed mouse fibroblasts and human melanoma cells
por: Kielosto, Mari, et al.
Publicado: (2018) -
Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1α in Melanoma Cells
por: Spinella, Francesca, et al.
Publicado: (2010)